PAWR and cholangiocarcinoma: Significant reduction of Par-4-activity was documented in almost all examined tumor-types, among others in kidney- [23], different neurological [24, 25], endometrial [26], breast- [27], prostate- [28], colon- [29] as well as in cholangiocarcinoma-cells [30] thus confirming that reduced Par-4-activity is an important feature of tumor cells.